These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15660031)

  • 1. Metabolic syndrome: evaluation of pathological and therapeutic outcomes.
    Miranda PJ; DeFronzo RA; Califf RM; Guyton JR
    Am Heart J; 2005 Jan; 149(1):20-32. PubMed ID: 15660031
    [No Abstract]   [Full Text] [Related]  

  • 2. [Progress in clinical care of cardiovascular diseases complicated with diabetes mellitus].
    Sone H; Yamada N
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):794-801. PubMed ID: 19472542
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA; Nicholls SJ; Lincoff AM
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy for metabolic syndrome].
    Node K
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1737-41. PubMed ID: 17037308
    [No Abstract]   [Full Text] [Related]  

  • 5. Metformin for Antipsychotic-Related Metabolic Syndrome in Children: Fact or Fiction?
    Naguy A; El-Sori D
    Chin Med J (Engl); 2018 Jun; 131(12):1490-1491. PubMed ID: 29893366
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of metformin on exercise capacity in metabolic syndrome.
    Paul AA; Dkhar SA; Kamalanathan S; Thabah MM; George M; Chandrasekaran I; Gunaseelan V; Selvarajan S
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S403-S406. PubMed ID: 28283393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atherosclerosis and the vulnerable plaque--pathogenesis: Part I.
    Worthley SG; Helft G; Zaman AG; Fuster V; Badimon JJ
    Aust N Z J Med; 2000 Oct; 30(5):600-7. PubMed ID: 11108071
    [No Abstract]   [Full Text] [Related]  

  • 8. Summaries for patients. The effect of diet and exercise or metformin on the metabolic syndrome.
    Ann Intern Med; 2005 Apr; 142(8):I46. PubMed ID: 15838061
    [No Abstract]   [Full Text] [Related]  

  • 9. The Diabetes Prevention Program and the metabolic syndrome.
    Sarinas PS; Dube DS
    Ann Intern Med; 2005 Oct; 143(7):544-5; author reply 545-6. PubMed ID: 16204171
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of surrogate or intermediate endpoints for assessing the effects of hypertension on atherosclerosis and its complications in man.
    Chobanian AV
    Blood Press Suppl; 1997; 2():103-7. PubMed ID: 9495637
    [No Abstract]   [Full Text] [Related]  

  • 11. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin for cardiovascular disease: promise still unproven.
    Lexis CP; van der Horst IC
    Lancet Diabetes Endocrinol; 2014 Feb; 2(2):94-5. PubMed ID: 24622700
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hypertension and arteriosclerosis].
    Sasamura H; Itoh H
    Nihon Rinsho; 2011 Jan; 69(1):125-30. PubMed ID: 21226272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of insulin sensitizers in diabetes.
    Jawa A; Fonseca V
    Curr Opin Investig Drugs; 2006 Sep; 7(9):806-14. PubMed ID: 17002258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary.
    ; ; Grundy SM; Cleeman JI; Daniels SR; Donato KA; Eckel RH; Franklin BA; Gordon DJ; Krauss RM; Savage PJ; Smith SC; Spertus JA; Costa F
    Cardiol Rev; 2005; 13(6):322-7. PubMed ID: 16708441
    [No Abstract]   [Full Text] [Related]  

  • 16. Beneficial effects of insulin on endothelial function, inflammation, and atherogenesis and their implications.
    Kuritzky L; Nelson SE
    J Fam Pract; 2005 Jun; 54(6):S7-9. PubMed ID: 16021783
    [No Abstract]   [Full Text] [Related]  

  • 17. The cardiovascular effects of peroxisome proliferator-activated receptor agonists.
    Friedland SN; Leong A; Filion KB; Genest J; Lega IC; Mottillo S; Poirier P; Reoch J; Eisenberg MJ
    Am J Med; 2012 Feb; 125(2):126-33. PubMed ID: 22269613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial dysfunction and the metabolic syndrome.
    McVeigh GE; Cohn JN
    Curr Diab Rep; 2003 Feb; 3(1):87-92. PubMed ID: 12643151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
    Caro JJ; Getsios D; Caro I; Klittich WS; O'Brien JA
    Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.